CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Preexposure prophylaxis for prevention of HIV acquisition among adolescents : clinical considerations, 2020
-
04/24/2020
-
-
Source: Preexposure prophylaxis for prevention of HIV acquisition among adolescents : clinical considerations, 2020. MMWR Recomm Rep 2020;69(No. RR-3
Details:
-
Alternative Title:MMWR Recommendations and Reports
-
Journal Article:MMWR. Recommendations and Reports
-
Personal Author:
-
Corporate Authors:
-
Description:Preexposure prophylaxis (PrEP) with antiretroviral medication has been proven effective in reducing the risk for acquiring human immunodeficiency Virus (HIV). The fixed-dose combination tablet of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) was approved by the U.S. Food and Drug Administration (FDA) for use as PrEP for adults in 2012. Since then, recognition has been increasing that adolescents at risk for acquiring HIV can benefit from PrEP. In 2018, FDA approved revised labeling for TDF/FTC that expanded the indication for PrEP to include adolescents weighing at least 77 lb (35 kg) who are at risk for acquiring HIV. In 2019, FDA approved the combination product tenofovir alafenamide (TAF)/FTC as PrEP for adolescents and adults weighing at least 77 lb (35 kg), excluding those at risk for acquiring HIV through receptive vaginal sex. This exclusion is due to the lack of clinical data regarding the efficacy of TAF/FTC in cisgender women.
-
Subjects:
-
Source:
-
Series:
-
Document Type:
-
Place as Subject:
-
Volume:69
-
Issue:3
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: